Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

467 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Diabetes and cardiovascular disease in older adults.
Bilal A, Pratley R. Bilal A, et al. Among authors: pratley r. Ann N Y Acad Sci. 2024 Dec 12. doi: 10.1111/nyas.15259. Online ahead of print. Ann N Y Acad Sci. 2024. PMID: 39666834 Review.
Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: a meta-analysis of randomised controlled trials.
Badve SV, Bilal A, Lee MMY, Sattar N, Gerstein HC, Ruff CT, McMurray JJV, Rossing P, Bakris G, Mahaffey KW, Mann JFE, Colhoun HM, Tuttle KR, Pratley RE, Perkovic V. Badve SV, et al. Among authors: pratley re. Lancet Diabetes Endocrinol. 2025 Jan;13(1):15-28. doi: 10.1016/S2213-8587(24)00271-7. Epub 2024 Nov 25. Lancet Diabetes Endocrinol. 2025. PMID: 39608381
Automated Insulin Delivery in Older Adults with Type 1 Diabetes.
Kudva YC, Henderson RJ, Kanapka LG, Weinstock RS, Rickels MR, Pratley RE, Chaytor N, Janess K, Desjardins D, Pattan V, Peleckis AJ, Casu A, Rizvi SR, Bzdick S, Whitaker KJ, Jo Kamimoto JL, Miller K, Kollman C, Beck RW. Kudva YC, et al. Among authors: pratley re. NEJM Evid. 2025 Jan;4(1):EVIDoa2400200. doi: 10.1056/EVIDoa2400200. Epub 2024 Dec 23. NEJM Evid. 2025. PMID: 39714936 Clinical Trial.
Cardiovascular and renal outcomes with varying degrees of kidney disease in high-risk people with type 2 diabetes: An epidemiological analysis of data from the AMPLITUDE-O trial.
Gerstein HC, Mian R, Ramasundarahettige C, Branch KRH, Del Prato S, Lam CSP, Lopes RD, Pratley R, Rosenstock J, Sattar N. Gerstein HC, et al. Among authors: pratley r. Diabetes Obes Metab. 2024 Apr;26(4):1216-1223. doi: 10.1111/dom.15417. Epub 2023 Dec 20. Diabetes Obes Metab. 2024. PMID: 38116691
Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes.
Perkovic V, Tuttle KR, Rossing P, Mahaffey KW, Mann JFE, Bakris G, Baeres FMM, Idorn T, Bosch-Traberg H, Lausvig NL, Pratley R; FLOW Trial Committees and Investigators. Perkovic V, et al. Among authors: pratley r. N Engl J Med. 2024 Jul 11;391(2):109-121. doi: 10.1056/NEJMoa2403347. Epub 2024 May 24. N Engl J Med. 2024. PMID: 38785209 Clinical Trial.
Hypoglycaemia and kidney events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: Observations from the VERTIS CV trial.
Odutayo A, Cosentino F, Pratley RE, Dagogo-Jack S, McGuire DK, Frederich R, Fu W, Cannon CP, Cherney DZI; VERTIS CV Investigators. Odutayo A, et al. Among authors: pratley re. Diabetes Obes Metab. 2024 Aug;26(8):3478-3481. doi: 10.1111/dom.15687. Epub 2024 Jun 5. Diabetes Obes Metab. 2024. PMID: 38840474 Clinical Trial. No abstract available.
467 results